info@salutesicilia.com

Targeting IPF with both artificial intelligence and drug repurposing: promises for redemption

Targeting IPF with both artificial intelligence and drug repurposing: promises for redemption

Medicomunicare Magazine | Health and Medical News

Insilico Medicine (“Insilico”), an end-to-end artificial intelligence (AI)-driven drug discovery company announced that it has dosed multiple healthy volunteers in Phase I clinical trial evaluating ISM001-055, the first anti-fibrotic small molecule inhibitor generated by Insilico’s AI-powered drug discovery platform for idiopathic pulmonary fibrosis (IPF). The double-blind, placebo controlled single and multiple ascending dose ISM001-055 is

Read More

Generated by Feedzy